Page 42 - Haematologica Vol. 110 - January 2025

REVIEW ARTICLE - Molecular pathogenesis and novel treatments for CMML L. Marando et al.
58. Patnaik MM, Pophali PA, Lasho TL, et al. Clinical correlates, prognostic impact and survival outcomes in chronic myelomonocytic leukemia patients with the JAK2V617F mutation. Haematologica. 2019;104(6):e236-e239.
59. Patnaik MM, Timm MM, Vallapureddy R, et al. Flow cytometry based monocyte subset analysis accurately distinguishes chronic myelomonocytic leukemia from myeloproliferative neoplasms with associated monocytosis. Blood Cancer J. 2017;7(7):e584.
60. Padron E, Painter JS, Kunigal S, et al. GM-CSF-dependent pSTAT5 sensitivity is a feature with therapeutic potential in chronic myelomonocytic leukemia. Blood. 2013;121(25):5068-5077.
61. Patnaik MM, Sallman DA, Mangaonkar AA, et al. Phase 1 study of lenzilumab, a recombinant anti-human GM-CSF antibody, for chronic myelomonocytic leukemia. Blood. 2020;136(7):909-913.
62. Hiwase D, Ross DM, Steven W, et al. Lenzilumab in addition to azacitidine improves complete response rates in chronic myelomonocytic leukemia. Blood. 2023;142(Supplement 1):1847.
63. Watanabe S, Itoh T, Arai K. Roles of JAK kinases in human GM-CSF receptor signal transduction. J Allergy Clin Immunol. 1996;98(6 Pt 2):S183-191.
64. Padron E, Dezern A, Andrade-Campos M, et al. Myelodysplastic Syndrome Clinical Research Consortium. A multi-institution phase I trial of ruxolitinib in patients with chronic myelomonocytic leukemia (CMML). Clin Cancer Res. 2016;22(15):3746-3754.
65. Selimoglu-Buet D, Wagner-Ballon O, Saada V, et al. Characteristic repartition of monocyte subsets as a diagnostic signature of chronic myelomonocytic leukemia. Blood. 2015;125(23):3618-3626.
66. Franzini A, Pomicter AD, Yan D, et al. The transcriptome of CMML monocytes is highly inflammatory and reflects leukemia- specific and age-related alterations. Blood Adv. 2019;3(20):2949-2961.
67. Elbæk MV, Sørensen AL, Hasselbalch HC. Cardiovascular disease in chronic myelomonocytic leukemia: do monocytosis and chronic inflammation predispose to accelerated atherosclerosis? Ann Hematol. 2019;98(1):101-109.
68. Mekinian A, Grignano E, Braun T, et al. Systemic inflammatory and autoimmune manifestations associated with myelodysplastic syndromes and chronic myelomonocytic leukaemia: a French multicentre retrospective study. Rheumatology (Oxford). 2016;55(2):291-300.
69. Papo M, Diamond EL, Cohen-Aubart F, et al. High prevalence of myeloid neoplasms in adults with non-Langerhans cell histiocytosis. Blood. 2017;130(8):1007-1013.
70. Bonnet P, Chasset F, Moguelet P, et al. Erdheim-Chester disease associated with chronic myelomonocytic leukemia harboring the same clonal mutation. Haematologica. 2019;104(11):e530-e533.
71. Ghobadi A, Miller CA, Li T, et al. Shared cell of origin in a patient with Erdheim-Chester disease and acute myeloid leukemia. Haematologica. 2019;104(8):e373-e375.
72. Pietras EM, Mirantes-Barbeito C, Fong S, et al. Chronic interleukin-1 exposure drives haematopoietic stem cells towards precocious myeloid differentiation at the expense of self-renewal. Nat Cell Biol. 2016;18(6):607-618.
73. Meisel M, Hinterleitner R, Pacis A, et al. Microbial signals drive pre-leukaemic myeloproliferation in a Tet2-deficient host. Nature. 2018;557(7706):580-584.
74. Zhang Q, Zhao K, Shen Q, et al. Tet2 is required to resolve
inflammation by recruiting Hdac2 to specifically repress IL-6.
Nature. 2015;525(7569):389-393.
75. Cull AH, Snetsinger B, Buckstein R, Wells RA, Rauh MJ. Tet2
restrains inflammatory gene expression in macrophages. Exp
Hematol. 2017;55:56-70.
76. Abegunde SO, Buckstein R, Wells RA, Rauh MJ. An inflammatory
environment containing TNFa favors Tet2-mutant clonal
hematopoiesis. Exp Hematol. 2018;59:60-65.
77. Cai Z, Kotzin JJ, Ramdas B, et al. Inhibition of inflammatory signaling in Tet2 mutant preleukemic cells mitigates stress- induced abnormalities and clonal hematopoiesis. Cell Stem
Cell. 2018;23(6):833-849.
78. Lee SC, North K, Kim E, et al. Synthetic lethal and convergent
biological effects of cancer-associated spliceosomal gene
mutations. Cancer Cell. 2018;34(2):225-241.
79. Smith MA, Choudhary GS, Pellagatti A, et al. U2AF1 mutations
induce oncogenic IRAK4 isoforms and activate innate immune pathways in myeloid malignancies. Nat Cell Biol. 2019;21(5):640-650.
80. Sevin M, Debeurme F, Laplane L, et al. Cytokine-like protein 1-induced survival of monocytes suggests a combined strategy targeting MCL1 and MAPK in CMML. Blood. 2021;137(24):3390-3402.
81. Castaño-Díez S, López-Guerra M, Bosch-Castañeda C, et al. Real-world data on chronic myelomonocytic leukemia: clinical and molecular characteristics, treatment, emerging drugs, and patient outcomes. Cancers (Basel). 2022;14(17):4107.
82. Santini V, Allione B, Zini G, et al. A phase II, multicentre trial of decitabine in higher-risk chronic myelomonocytic leukemia. Leukemia. 2018;32(2):413-418.
83. Coston T, Pophali P, Vallapureddy R, et al. Suboptimal response rates to hypomethylating agent therapy in chronic myelomonocytic leukemia; a single institutional study of 121 patients. Am J Hematol. 2019;94(7):767-779.
84. Coltro G, Mangaonkar AA, Lasho TL, et al. Clinical, molecular, and prognostic correlates of number, type, and functional localization of TET2 mutations in chronic myelomonocytic leukemia (CMML) - a study of 1084 patients. Leukemia. 2020;34(5):1407-1421.
85. Schnegg-Kaufmann AS, Thoms JAI, Bhuyan GS, et al. Contribution of mutant HSC clones to immature and mature cells in MDS and CMML, and variations with AZA therapy. Blood. 2023;141(11):1316-1321.
86. Itzykson R, Solary E. An evolutionary perspective on chronic myelomonocytic leukemia. Leukemia. 2013;27(7):1441-1450. 87. Guan Y, Greenberg EF, Hasipek M, et al. Context dependent
effects of ascorbic acid treatment in TET2 mutant myeloid
neoplasia. Commun Biol. 2020;3(1):493.
88. DiNardo CD, Jonas BA, Pullarkat V, et al. Azacitidine and
venetoclax in previously untreated acute myeloid leukemia. N
Engl J Med. 2020;383(7):617-662.
89. Tremblay D, Csizmar CM, DiNardo CD, et al. Venetoclax (VEN)
improves response rates but not survival in patients with chronic myelomonocytic leukemia (CMML) treated with hypomethylating agents (HMA): a multicenter, propensity score analysis. Blood. 2023;142(Supplement 1):321.
90. Pei S, Pollyea DA, Gustafson A, et al. monocytic subclones confer resistance to venetoclax-based therapy in patients with acute myeloid leukemia. Cancer Discov. 2020;10(4):536-551.
91. Punekar SR, Velcheti V, Neel BG, Wong KK. The current state of the art and future trends in RAS-targeted cancer therapies. Nat Rev Clin Oncol. 2022;19(10):637-655.
Haematologica | 110 January 2025
34